RARE Daily

QurAlis Clears FDA Hurdle for Pivotal Trial of Experimental ALS Drug

November 16, 2026

Rare Daily Staff

QurAlis said the U.S. Food and Drug Administration has cleared its application to begin U.S. clinical testing of QRL-201, an experimental treatment for the rare neurodegenerative disease amyotrophic lateral sclerosis, as the company reported early trial results suggesting the drug may slow patients’ functional decline.

The company plans to launch a pivotal trial, called CONQUR, in the first half of 2027. The study would seek to establish evidence needed to support a potential application for approval.

The company also reported final results from the dose-range-finding portion of its phase 1/2 ANQUR trial. That portion enrolled 52 participants and compared two doses of QRL-201—3 milligrams and 10 milligrams—with placebo.

At day 253, participants receiving the 10-milligram dose had a 50 percent slower rate of functional decline than those receiving placebo, as measured by the ALS Functional Rating Scale–Revised, or ALSFRS-R, the company said. The difference was statistically significant. Participants receiving the lower dose also showed slower decline, although the release did not report the size or statistical significance of that functional benefit.

The finding represents a reduction in the rate of worsening. QurAlis did not provide the underlying changes in functional scores, the number of participants in each treatment group, or confidence intervals in its announcement, limiting assessment of the result’s magnitude and precision.

QRL-201 is an antisense oligonucleotide designed to restore production of STATHMIN-2, a protein that helps maintain nerve fibers and their connections to muscles. The company says levels of the protein are reduced in most people with ALS.

The reported efficacy results involved people with sporadic ALS, meaning cases without an identified family history of the disease. The broader ANQUR study was designed to include people with sporadic ALS and ALS associated with changes in the C9orf72 gene.

“The findings from the ANQUR clinical trial are promising and justify additional clinical research into QRL-201 as a potential treatment option for individuals with sporadic ALS,” said Merit Cudkowicz, director of the Sean M. Healey & AMG Center for ALS and a member of QurAlis’ clinical advisory board.

QurAlis also reported reductions in neurofilaments, proteins measured as indicators of nerve-fiber damage. In the 3-milligram group, levels of phosphorylated neurofilament heavy in cerebrospinal fluid fell 46 percent from baseline at day 197, the last time point measured. That change was statistically significant.

Blood levels of another marker, neurofilament light, fell 18 percent from baseline in the 3-milligram group at day 337 and 36 percent in the 10-milligram group at day 421. Both changes were statistically significant.

However, the reported 31 percent reduction in blood neurofilament light compared with placebo in the lower-dose group did not meet the conventional threshold for statistical significance. The distinction matters because a change from a patient’s starting level is a different comparison from a treatment’s effect relative to placebo.

The company described QRL-201 as generally well tolerated, with most adverse events mild or moderate. It reported no serious adverse events during the dose-range-finding portion of the trial.

ANQUR has now moved entirely into an open-label extension, in which 41 participants are receiving the 3-milligram dose in Canada, the United Kingdom, and the European Union. QurAlis said it expects to disclose more details about the planned pivotal trial in early 2027.

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube